# Agenus (AGEN)

Agenus to Withdraw BLA for Balstilimab Agenus ( AGEN ) announced a strategic decision to withdraw its Biologics License Application ( BLA ) for balstilimab, its PD-1 inhibitor. The firm stated that it...

Prohost Biotech

Jun 5, 2024

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

Prohost Biotech

Oct 22, 2021

0

Agenus Good News for Balstilimab Monotherapy Agenus (AGEN) announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published...

Agenus Good News: Balstilimab Monotherapy Data Published in Gynecologic Oncology

Agenus Inc News and Q2 Results for 201 Agenus ( AGEN ) announced results with better than usual news including the following: $200 million received from BMS for anti-TIGIT bispecific antibody collabo...

Prohost Biotech

Aug 27, 2021

Agenus Inc Corporate Update and Financial Results for Q2 2021. See Also: Why Intellia Was Down Today

Bristol-Myers Squibb and Agenus Agreement for AGEN1777 Bristol-Myers Squibb ( BMY ) and Agenus ( AGEN ) today announced that they have entered into a definitive agreement under which Bristol Myers Squ...

Prohost Biotech

Aug 9, 2021

An Important Agreement Between Bristol-Myers Squibb and Agenus

Why Agenus Stock Rallied Yesterday On September 2, 2020 we posted an article about Agenus ( AGEN ) under Trick or Trade titled, “ Agenus: Could It Be a Resurrection? " The article was about the data...

Prohost Biotech

May 18, 2021

Agenus Stock Rallied Yesterday

Agenus Announced Data from Phase 2 Trials of Balstilimab Agenus ( AGEN ) immuno-oncology company announced that data from two Phase 2 trials of balstilimab alone and in combination with zalifrelimab w...

Prohost Biotech

Sep 11, 2020

Agenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

Agenus Has Two Separate Press Releases In the First Press Release from Agenus: Agenus ( AGEN ) announced that it will be making a scientific presentation today on optimal anti-cancer combinations with...

Prohost Biotech

Sep 2, 2020

The Time Has Come for Agenus to Excel. See Also: Why Evoke Pharma Traded UP Today

Presenting UroGen Pharma UroGen Pharma ( URGN ) focuses on cancers and urologic diseases. It announced its fourth quarter and full-year ended December 31, 2019 financial results. The announcement star...

Prohost Biotech

Jun 22, 2020

We Introduce UroGen Pharma and Discuss Its Pipeline of Products

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week Highs The three picks referred to in the above title are, Novartis (NVS), Array (AARY) and Ionis (IONS)...

Prohost Biotech

Apr 2, 2020

During the Departed Week

AGENUS Agenus (AGEN) announced the upcoming launch of its Biotech Electronic Security Token (BEST); the first digital security offering in healthcare. Tokenization enables qualified investors to dir...

Prohost Biotech

Mar 19, 2019

Agenus fincances through Tokenization. Amgen's critics hit hard. Why BioTime could thrive on OncoCyte news

Prohost Biotech

Jan 30, 2019

2

Agenus (AGEN) announced recently that it entered into an immuno-oncology (I-O) partnership with Gilead Sciences (GILD). The partnership is focused on developing and commercializing up to five novel I-...

Agenus: Signing a lucrative and rewarding agreement with Gilead

Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week in Review into the Prohost Letter this time. We thought it would be easier for the readers to get last week’s upda...

Prohost Biotech

Dec 20, 2018

Prohost Letter #414

Agenus (AGEN) announced that The Food and Drug Administration (FDA) granted marketing authorization to GlaxoSmithKline's (GSK) product Shingrix, a herpes zoster vaccine containing Agenus' proprietary...

Prohost Biotech

Oct 25, 2017

Agenus' Double News

The Week in Review #4 AMAZING STOCK REBOUNDING - We have already witnessed and wrote about the fierce rebounding of some of our selected stocks comprising: Exelixis (EXEL), Sangamo (SGMO), Array (ARRY...

Prohost Biotech

Oct 23, 2017

Some Small Outperforming Biotech Firms

Prohost Biotech

Sep 18, 2017

7

Agenus (AGEN) announced that the U.S. Food and Drug Administration (FDA) Advisory Committee voted unanimously, recommending the approval of GlaxoSmithKline's (GSK) shingles vaccine candidate, Shingrix...

Agenus Has Good News

Prohost Letter #412 Part 3 GLIOBLASTOMA - Is There Hope? Senator John McCain was diagnosed with a malignant brain tumor, glioblastoma – the most common and aggressive form of brain cancer. The cancer...

Prohost Biotech

Sep 15, 2017

Prohost Letter #412 Part 3

Agenus (AGEN ) is reorganizing its business and operations. The reasons the firm cited comprise sharpening of its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine p...

Prohost Biotech

Aug 3, 2017

Agenus Reform and Downsizing. Innoviva's Voting Dilemma

Incyte Announces a Multi-year Research Collaboration with the Abramson Cancer Center at the University of Pennsylvania . The aim of the agreement with Abramson Cancer Center at the University of Penns...

Prohost Biotech

Mar 30, 2017

Incyte: A Thoughtful Research and Collaboration Agreement with Abramson Cancer Center

Prohost Biotech

Feb 24, 2017

0

Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore with Agenus’ totally changed status now with its new immunotherapy pipeline. The new checkpoint inhi...

Agenus: Why Canceling Prophage Trial Should Not be Concerning